Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.

Trial Details

NCT ID
NCT04838041
Phase
PHASE2
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Asciminib 40 MG
  • Asciminib 40 MG Twice Daily
  • Asciminib 80 MG daily
  • Imatinib
  • Nilotinib
  • Dasatinib
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Buffalo, New York, United States|42.88645,-78.87837
  • New York, New York, United States|40.71427,-74.00597
  • Salt Lake City, Utah, United States|40.76078,-111.89105
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Age ≥18 years old.
  • Willing and able to give informed consent.
  • Diagnosed with chronic myelogenous leukemia (CML) in chronic phase without BCR::ABL1 \^T315I and have either the b3a2 (e14a2) or b2a2 (e13a2) varia…
  • Must have a documented history of attempting only one prior TKI discontinuation under the guidance of a treating physician. TKI includes dasatinib,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →